Treatment of depression in children and adolescents

Journal of Psychiatric Practice

Volumn 11, Issue 3, 2005, Pages 141-154

  Bostic, Jeff Q ^a   Rubin, David H ^a   Prince, Jefferson ^a   Schlozman, Steven ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adolescents; Antidepressants; Atypical antidepressants; Children; Depression; Major depressive disorder; Selective serotonin reuptake inhibitors; Tricyclic antidepressants

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; VIVACTYL;

AGITATION; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG INDICATION; DRUG INFORMATION; EVIDENCE BASED MEDICINE; FOOD DRUG INTERACTION; GROWTH DISORDER; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; LIVER TOXICITY; MAJOR DEPRESSION; META ANALYSIS; NAUSEA; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOTHERAPY; SEDATION; SHORT SURVEY; SIDE EFFECT; STOMACH PAIN; SUDDEN DEATH; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; VISUAL IMPAIRMENT; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; NOREPINEPHRINE; PSYCHOTHERAPY; SEROTONIN UPTAKE INHIBITORS;

EID: 19944397491     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200505000-00002     Document Type: Short Survey

References (101)

1. Puig-Antich J, Lukens E, Davies M, et al. Psychosocial functioning in prepubertal major depressive disorders: II. Interpersonal relationships after sustained recovery from affective episode. Arch Gen Psychiatry 1985;42:511-7.
2. Lewinsohn PM, Clarke GN, Seeley JR, et al. Major depression in community adolescents: Age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry 1994;33:809-18.
3. Fleming JE, Offord DR. Epidemiology of childhood depressive disorders: A critical review. J Am Acad Child Adolesc Psychiatry 1990;29:571-80.
4. McCauley E, Myers K, Mitchell J, et al. Depression in young people: Initial presentation and clinical course. J Am Acad Child Adolesc Psychiatry 1993;32:714-22.
5. Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996;35:705-15.
6. Harrington RC. Adult outcomes of childhood and adolescent depression: Influences on the risk for adult depression. Psychiatric Ann 1996;26:320-5.
7. Puig-Antich J, Goetz D, Davies M, et al: A controlled family history study of prepubertal major depressive disorder. Arch Gen Psychiatry 1989;46:406-18.
8. Aylward GP. Understanding and treatment of childhood depression. J Pediatr 1985;107:1-9.
9. Kaminski KM, Naylor MW, King CA, et al. Reactive mood and atypical depression in psychiatrically hospitalized depressed adolescents. Depression 1995;3:176-81.
10. Kashani JH, Sherman DD. Mood disorders in children and adolescents. In: Review of psychiatry. Washington, DC: American Psychiatric Press; 1989:197-217.
11. Chambers WJ, Puig-Antich J, Tabrizi MA, et al. Psychotic depression symptoms in prepubertal major depressive disorder. Arch Gen Psychiatry 1982;39:921-7.
12. Geller B, Fox LW, Clark KA. Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children. J Am Acad Child Adolesc Psychiatry 1994;33:461-8.
13. Bowden CL, Rhodes LJ. Mania in children and adolescents: Recognition and treatment. Psychiatric Ann 1996;26 (Suppl):S430-4.
14. Martin A, Young C, Leckman JF, et al. Age effects on antidepressant- induced manic conversion. Arch Pediatr Adolesc Med 2004;158:773-80.
15. Moreau DL. Major depression in childhood and adolescence. Psychiatric Clin N Am 1990;13:355-68.
16. Bostic JQ, Wilens, TE, Spencer T, et al. Juvenile mood disorders and office psychopharmacology. Ped Clin N Am 1997;44:1487-1503.
17. Ohberg A, Lonnqvist J, Sarna S, et al. Violent methods associated with high suicide mortality among the young. J Am Acad Child Adolesc Psychiatry 1996;35:144-53.
18. Pfeffer CR, Klerman GL, Hurt SW, et al. Suicidal children grow up: Rates and psychosocial risk factors for suicide attempts during follow-up. J Am Acad Child Adolesc Psychiatry 1993;32:106-13.
19. Grunbaum JA, Kann L, Kinchen SA, et al. Youth risk behavior surveillance-United States, 2001. MMWR Surveill Summ 2002;51:1-64.
20. Fassler D. Presented at the Joint Meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee, Bethesda, MA, September 13, 2004. Can be accessed at www.fda.gov/ohrms/dockets/ac/04/ transcripts/2004-4065T1.htm (pp. 298-301).
21. Boyd JH, Moscicki EK. Firearms and youth suicide. Am J Pub Health 1986;76:1232-42.
22. Brent DA, Holder D, Kolko D, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry 1997;54:877-85.
23. Harrington R, Whittaker J, Shoebridge P, et al. Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depression. BMJ 1998;316:1559-63.
24. Reinecke MA, Ryan NE, DuBois DL. Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: A review and meta-analysis. J Am Acad Child Adolesc Psychiatry 1998;37:26-34.
25. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807-20.
26. Barbe RP, Bridge JA, Birmaher B, et al. Lifetime history of sexual abuse, clinical presentation, and outcome in a clinical trial for adolescent depression. J Clin Psychiatry 2004;65:77-83.
27. Mufson L, Dorta KP, Wickramaratne P, et al. A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 2004;61:577-84.
28. Sholevar GP. Family therapy. In: Wiener JM, ed. Textbook of child and adolescent psychiatry, 2nd edition. Washington, DC: American Psychiatric Press; 1996;857-78.
29. Birmaher B. Should we use antidepressant medications for children and adolescents with depressive disorders? Psychopharmacol Bull 1998;34:35-9.
30. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762-72.
31. Ryan ND, Puig-Antich J, Rabinovich H, et al. MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. J Am Acad Child Adolesc Psychiatr 1988;27:755-8.
32. Rush AJ, Golden WE, Hall GW, et al. Depression in primary care: Vol. 2. Treatment of major depression. Clinical practice guideline, number 5. Rockville, MD. US Dept. of Health & Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication: 1993;93-0551.
33. Delate T, Gelenberg AJ, Simmons VA, et al. Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatr Serv 2004;55:387-91.
34. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: A propensity-adjusted retrospective cohort study. CNS Drugs 2004;18:1119-32.
35. Simeon JG, Dinicola VF, Ferguson HB, et al. Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:791-5.
36. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized placebo-controlled trial of fluoxetine in depressed children and adolescents. Arch Gen Psychiatry 1997;54:1031-7.
37. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002;41:1205-15.
38. Paroxetine unipolar major depression study 377 (1998). Available at http://www.gsk.com/media/paroxetine.htm.
39. Paroxetine major depressive disorder study 701 (2001). Available at http://www.gsk.com/media/paroxetine.htm.
40. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: Two randomized controlled trials. JAMA 2003;290:1033-41.
41. Wagner KD, Robb AS, Findling RL, et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004;161:1079-83.
42. Citalopram study 2 (Available at http://www.mca.gov.uk/ourwork/ monitorsafequalmed/safetymessages/ssrioverviewclintrialdata_101203.htm).
43. Wagner KD, Jonas J, Bose A, et al. Controlled trial of escitalopram in pediatric depression. Presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 18-24, 2004.
44. Emslie GJ, Rush AJ, Weinberg WA, et al. Fluoxetine in child and adolescent depression: Acute and maintenance treatment. Depress Anxiety 1998;7:32-9.
45. Nilsson M, Joliat MJ, Miner CM, et al. Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychopharmacol 2004;14:412-7.
46. Weintrob N, Cohen D, Klipper-Aurbach Y, et al. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 2002;156:696-701.
47. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
48. Emslie GJ. A double-blind placebo controlled study of nefazodone in depressed children and adolescents. Presented at the Annual Meeting of the New Drug Clinical Evaluation Unit, 2002.
49. Emslie GJ. Treatment of major depressive disorder in children and adolescents. Presented at the 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Honolulu, HI, October 25, 2001.
50. Mandocki MW, Tapia MR, Tapia MA, et al. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 1997;33:149-54.
51. Emslie, GE, Yeung, PP, Kunz, NR, et al. Long-term venlafaxine ER treatment of pediatric patients with major depressive disorder. American Academy of Child and Adolescent Psychiatry, 51st Annual Meeting, Washington, DC, 2004.
52. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 2004;363:1341-5.
53. Kramer AD, Feiguine RJ. Clinical effects of amitriptyline in adolescent depression. J Am Acad Child Psychiatry 1981;20:636-44.
54. Petti TA, Law WL III. Imipramine treatment of depressed children: A double-blind pilot study. J Clin Psychopharmacol 1982;2:107-10.
55. Kashani JH, Shekim WO, Reid JC. Amitriptyline in children with major depressive disorder: A double-blind crossover pilot study. J Am Acad Child Psychiatry 1984;23:348-51.
56. Preskorn SH, Weller EB, Hughes CW, et al. Depression in prepubertal children: Dexasmethasone nonsuppression predicts differential response to imipramine vs. placebo. Psychopharmacol Bull 1987;23:128-33.
57. Puig-Antich J, Perel JM, Lupatkin W, et al. Imipramine in prepubertal major depressive disorders. Arch Gen Psychiatry 1987;44:81-9.
58. Geller B, Cooper T, McCombs HG, et al. Double-blind, placebo-controlled study of nortriptyline in depressed children using a "fixed plasma level" design. Psychopharmacol Bull 1989;25:101-8.
59. Geller B, Cooper T, Graham D, et al. Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder. J Am Acad Child Adolesc Psychiatry 1992;31:34-44.
60. Hughes DC, Preskorn SH, Wrona M, et al.: Follow up of adolescents initially treated for prepubertal-onset major depressive disorder with imipramine. Psychopharmacol Bull 1990;26:244-8.
61. Geller B, Cooper T, Graham D, et al. Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a "fixed plasma level" design. Psychopharmacol Bull 1990;26:85-90.
62. Koplewicz H, Klein R: Desipramine treatment in adolescent depression. Child Depression Consortium Meeting, Pittsburgh, PA, 1990.
63. Kutcher S, Boulos C, Ward B, et al. Response to desipramine treatment in adolescent depression: A fixed-dose, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 1994;33:686-94.
64. Kye C, Waterman GS, Ryan ND, et al. A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. J Am Acad Child Adolesc Psychiatry 1996;35:1139-44.
65. Birmaher B, Waterman GS, Ryan ND, et al. Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment- resistant" major depression. J Am Acad Child Adolesc Psychiatry 1998;37:527-35.
66. Hazell P, O'Connell D, Heathcote D, et al. Efficacy of tricyclic drugs in treating child and adolescent depression: A meta-analysis. BMJ 1995;310:897-901.
67. Geller B, Todd RD, Luby J, et al. Treatment-resistant depression in children and adolescents. Psychiatr Clin N Am 1996;19:253-67.
68. Goldman-Rakic PS, Brown RM. Postnatal development of monoamine content and synthesis in the cerebral cortex of rhesus monkeys. Brain Res 1982;256:339-49.
69. Braconnier A, Le Coent R, Cohen D. Paroxetine versus clomipramine in adolescents with severe major depression: A double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 2003;42:22-9.
70. Are SSRIs safe for children? The Medical Letter. 2003;1160:53-4.
71. FDA Talk Paper. "FDA Statement on Recommendations of the Psychopharmacologic Drugs and Pediatric Advisory Committees." September 16, 2004.
72. Brent DA. Antidepressants and pediatric depression-the risk of doing nothing. N Engl J Med 2004;351:1598-601.
73. Information on FDA warnings and statements can be accessed at www.fda.gov/cder/drug/antidepressants/default.htm
74. Information on this analysis can be accessed at www.fda.gov/ohrms/ dockets/ac/04/slides/4006s1.htm.
75. Cavanagh JT, Carson AJ, Sharpe M, et al. Psychological autopsy studies of suicide: A systematic review. Psychol Med 2003;33:395-405.
76. Gray D, Achilles J, Keller T, et al. Utah youth suicide study, phase I: Government agency contact before death. J Am Acad Child Adolesc Psychiatry 2002;41:427-34.
77. Olfson M, Shaffer D, Marcus SC, et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003;60:978-82.
78. Gibbons RD, Hur K, Bhaumik DK, et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005;62:165-72.
79. Rey J, Martin A. SSRIs and suicidality in juveniles: Review of the evidence and implications for clinical practice. Child Adolesc Psychiatr Clin N Am (in press).
80. Verkes RJ, Van der Mast RC, Hengeveld MW, et al. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression Am J Psychiatry 1998;155:543-7.
81. Riddle MA, King RA, Hardin MT, et al. Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1991;1:193-8.
82. Hammad T. Results of the analysis of suicidality in pediatric trials of newer antidepressants. In: Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. Joint Meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee, September 13, 2004; pp 152-200. Available at http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4065T1.pdf and http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4065S1.htm (accessed April 22, 2005).
83. Wilens TE, Biederman J, March J, et al. Absence of cardiovascular effects of sertraline in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;38:573-7.
84. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-45.
85. Apter JT, Kushner SF, Woolfolk RL. Bupropion/nortriptyline combinations for refractory depression. Ann Clin Psychiatry 1994;6:255-8.
86. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-3.
87. Stoll AL, Mayer PV, Kolbrener M, et al. Antidepressant-associated mania: A controlled comparison with spontaneous mania. Am J Psychiatry 1994;151:1642-5.
88. Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004;161:163-5.
89. Physicians' Desk Reference, 59th Edition. Montvale, NJ: Thomson PDR; 2005.
90. Biederman J, Thisted R, Greenhill L, et al. Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry 1995;56:87-93.
91. Hughes CW, Emslie GJ, Crismon ML, et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 1999;38:1442-54.
92. Emslie GJ, Hughes CW, Crismon ML, et al. A feasibility study of the childhood depression medication algorithm: The Texas Children's Medication Algorithm Project (CMAP). J Am Acad Child Adolesc Psychiatry 2004;43:519-27.
93. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry 1996;53:785-92.
94. Ambrosini PJ, Bianch MD, Metz C, et al. Evaluating clinical response of open nortriptyline pharmacotherapy in adolescent major depression. J Child Adolesc Psychopharm 1994;4:233-41.
95. Wagner KD. Depression across the ages. Presented at the 8th Annual U.S. Psychiatric & Mental Health Congress, New York City, 1995.
96. Ryan ND, Meyer V, Dachille S, et al. Lithium antidepressant augmentation in TCA-refractory depression in adolescents. J Am Acad Child Adolesc Psychiatry 1988;27:371-6.
97. Birmaher B, Brent DA, Benson RS. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 1998;37:1234-8.
98. Emslie GJ, Heiligenstein JH, Hoog SL, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: A double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004;43:1397-1405.
99. Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharm 1993;3:1-10.
100. Rapport MD, Carlson GA, Kelly KL, et al. Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 1993;32:333-42.
101. Kallepalli BR, Bhatara VS, Fogas BS, et al. Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. J Child Adolesc Psychopharm 1997;7:97-107.